Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μl CD4 T cells and undetectable plasma virus load

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 56-60

  Arnó, Albert ^a   Ruiz, Lidia ^a   Juan, Manel ^a   Jou, Antoni ^a   Balagué, Montserrat ^a   Khalil Zayat, M ^a   Marfil, Silvia ^a   Martínez Picado, Javier ^a   Martínez, Miguel Angel ^a   Romeu, Joan ^a   Pujol Borrell, Ricardo ^a   Lane, Clifford ^b   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; RECOMBINANT INTERLEUKIN 2; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD28; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 0033017140     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314831     Document Type: Article

References (27)

1. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
2. Pantaleo G. How immune-based interventions can change HIV therapy. Nature Med 1997;3:483-6.
3. + T cells in HIV-1-infected patients receiving highly antiretroviral therapy [abstract 496]. In: 6th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Infectious Disease Society of America, 1999.
4. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
5. Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990;59:783-836.
6. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27 Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-3.
7. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567-75.
8. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-6.
9. McMahon DK, Armstrong JA, Haung X, et al. A phase 1 study subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 1994;8:59-66.
10. Masur H, Ognibene F, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus infection. Ann Intern Med 1989;111:223-31.
11. Crowe SM, Carlin JB, Stewart KI, Lucas LR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
12. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus infected patients. J Infect Dis 1998;177:1080-3.
13. Pino-Otin MR, Juan M, de la Fuente MA, et al. CD50 (intercellular adhesion molecule-3) expressed at higher levels on memory than on naive human T cells but induces a similar calcium mobilization on both subsets. Tissue Antigens 1995;46:32-44.
14. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type I burden in human plasma. J Infect Dis 1994;170:1172-9.
15. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8.
16. Matthews JNS, Altman DG, Campbell MJ, Roystoon P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
17. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
18. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997;3:533-40.
19. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood 1993;81:1414-23.
20. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996;93:10405-10.
21. + CD28 cell population in the blood and lung of HIV-positive patients. J Acquir Immune Defic Syndr 1993;6:1194-204.
22. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993;69:106-16.
23. + CD28 lymphocytes in human immunodeficiency virus specific cytotoxic activity. J Virol 1996;70:2022-6.
24. Clark AGB, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. J Acquir Immune Defic Syndr 1992;5:52-9.
25. Pakker NG, Notermans DW, De Bour RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;2:208-4.
26. Wilhers-Ward ES, Amado RG, Koka PS, et al. Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nature Med 1997;3:1102-9.
27. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD. Rapid turnover of T lymphocyte in STV-infected rhesus macaques. Science 1998;279:1223-7.